Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Scientific Officer | October 04, 2024 | October 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date October 04, 2024 · Filed October 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 388,026 |
Ending reported balance
After 2024-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-10-04 · Grant · Acquired 230,645 · Balance 464,946 F1: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition. Row 2 · 2024-10-07 · Sale · Disposed 76,920 · Balance 388,026 F2: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.
F2: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2024 Filed Oct 8, 2024 20:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 76,920 | $0.56 | $43,305.96 |
DisclosureSEC source: 0001628280-24-042541 · wk-form4_1728420235.xml · nonDerivative · entry 2 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,026 F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 230,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042541 · wk-form4_1728420235.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,946 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:20 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 14,235 | $0.88 | $12,552.42 |
DisclosureSEC source: 0001628280-24-010281 · wk-form4_1710192010.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,301 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9112, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 22:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 428,248 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-005379 · wk-form4_1708121312.xml · derivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,248 Underlying: Common Stock · 428,248 shares Expires 2034-02-13 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 22:23 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 787 | $1.01 | $792.67 |
DisclosureSEC source: 0001628280-24-004287 · wk-form4_1707776584.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,536 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:39 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 67,695 | $0.73 | $49,417.35 |
DisclosureSEC source: 0001628280-23-036755 · wk-form4_1699043942.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,323 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6841 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:59 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 230,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-036463 · wk-form4_1698958731.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,018 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 20:48 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 16,806 | $0.84 | $14,117.04 |
DisclosureSEC source: 0001628280-23-007721 · wf-form4_167874051295561.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,373 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.89, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 51,179 shares represent restricted stock units. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 22:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 928 | $0.93 | $863.04 |
DisclosureSEC source: 0001628280-23-003759 · wf-form4_167649920502600.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,179 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 99,679 shares represent restricted stock units. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 1,000,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001628280-22-029260 · wf-form4_166802891805410.xml · derivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-11-07 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 21:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 97,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-004499 · wf-form4_164616896122495.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,107 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:21 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | Tax withholdingCommon Stock | 928 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-002507 · wf-form4_164487363627920.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,107 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Shares withheld by X4 Pharmaceuticals Inc. to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. F3 · balance_after: Of the shares of common stock reported, 5,357 shares represent unvested restricted stock units. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 21:07 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 8,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-005665 · wf-form4_161670641436695.xml · nonDerivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,035 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 22:28 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 121,150 | $6.60 Strike: $6.60 | $799,590.00 |
DisclosureSEC source: 0001628280-20-016956 · wf-form4_160686171893552.xml · derivative · entry 1 Taveras Arthur · CIK 0001830901 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,150 Underlying: Common Stock · 121,150 shares Expires 2030-11-29 F1 · derivative.exercise_date: 25% of the shares subject tot he option shall vest on November 30, 2021, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.